Severe Refractory Anemia in Primary Intestinal Lymphangiectasia. A Case Report

J Gastrointestin Liver Dis. 2015 Sep;24(3):369-73. doi: 10.15403/jgld.2014.1121.243.bal.

Abstract

Background: Primary intestinal lymphangiectasia (Waldmann's disease) is a rare disease characterized by dilated lymphatics in the small bowel leading to an exudative enteropathy with lymphopenia, hypoalbuminemia and hypogammaglobulinemia.

Case presentation: We report the case of a 23 year-old male who presented with chronic anemia and in whom primary intestinal lymphangiectasia was diagnosed. A low-fat diet along with nutritional therapy with medium-chain triglyceride supplementation improved the protein-losing enteropathy, but did not solve the anemia. Octreotide was also unsuccessful, and after attempting angiographic embolization therapy, limited small bowel resection together with antiplasmin therapy managed to correct the anemia and control the exudative enteropathy.

Conclusions: Although primary intestinal lymphangiectasia is usually adequately managed by nutritional therapy, complications such as anemia can occur and can prove to be a therapeutic challenge.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia / blood
  • Anemia / diagnosis
  • Anemia / etiology*
  • Anemia / therapy
  • Antifibrinolytic Agents / therapeutic use
  • Biopsy
  • Chronic Disease
  • Diet, Fat-Restricted
  • Dietary Supplements
  • Digestive System Surgical Procedures
  • Embolization, Therapeutic
  • Endoscopy, Gastrointestinal
  • Humans
  • Lymphangiectasis, Intestinal / complications*
  • Lymphangiectasis, Intestinal / diagnosis
  • Lymphangiectasis, Intestinal / therapy
  • Lymphedema / complications*
  • Lymphedema / diagnosis
  • Lymphedema / therapy
  • Male
  • Octreotide / therapeutic use
  • Protein-Losing Enteropathies / etiology
  • Protein-Losing Enteropathies / therapy
  • Severity of Illness Index
  • Treatment Outcome
  • Triglycerides / administration & dosage
  • Young Adult

Substances

  • Antifibrinolytic Agents
  • Triglycerides
  • Octreotide

Supplementary concepts

  • Waldmann disease